Big Pharma's Drug Failure May Be Small Personalized Rx Firm's Gain, PGx Researcher Says

A drug deemed unsafe or ineffective in a large pharmaceutical firm's clinical program may turn out to be the lead product in a smaller personalized medicine company's pipeline using pharmacogenomics strategies, according to Michael Phillips, who, as the director of pharmacogenomics at Genome Quebec, is currently leading a PGx study for Pfizer's failed hypercholesterolemia drug torcetrapib.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.